Intelligence · Clinical Development
Pipeline search results
Programs matching “cytarabine” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 22 pipeline programs matching "cytarabine" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
09
The First People's Hospital of Lianyungang
Acute Myeloid Leukaemia
1 trial -
Cytarabine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
3 trials -
Cytarabine
The First People's Hospital of Lianyungang
Leukemia
1 trial -
Cytarabine
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
1 trial -
Cytarabine
Hoffmann-La Roche
Leukemia, Myeloid, Acute
1 trial -
Intermediate-dose Cytarabine in Combination with Venetoclax
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
Placebo in combination with Cytarabine Injection
Moleculin Biotech
Acute Myeloid Leukaemia (AML)
1 trial -
Cytarabine
Jazz Pharmaceuticals Ireland Limited
Leukemia
1 trial -
Cytarabine
Teva Pharma GmbH
Acute Myeloid Leukemia
1 trial -
Cytarabine
Hospital Authority, Hong Kong
AML
1 trial -
Cytarabine
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Cytarabine (Phase 1 only)
Actinium Pharmaceuticals
AML
1 trial -
Cytarabine and Idarubicin
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
1 trial -
Liposome-encapsulated Daunorubicin-Cytarabine
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
2 trials -
Liposome-encapsulated Daunorubicin-Cytarabine
Jazz Pharmaceuticals Ireland Limited
Essential Thrombocythemia
1 trial -
Liposome-encapsulated Daunorubicin-Cytarabine
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
1 trial -
S2023-056-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
S2023-413-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Acute Myeloid Leukemia
1 trial -
cytarabine
Teva Pharma GmbH
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
1 trial -
cytarabine
Ultragenyx UK Limited
Lupus Erythematosus, Systemic
1 trial -
CPX-351 (Cytarabine:Daunorubicin) Liposome Injection
Jazz Pharmaceuticals Ireland Limited
Hematologic Neoplasms
1 trial -
liposomal cytarabine
Pacira Ireland Limited
Brain and Central Nervous System Tumors
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.